The vyepti market research report is one of a series of new reports that provides vyepti market statistics, including the vyepti industry global market size, regional shares, competitors with the vyepti market share, detailed vyepti market segments, market trends, and opportunities, and any further data you may need to thrive in the vyepti industry. This vyepti market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The growth in the forecast period can be attributed to shift towards personalized medicine, growth of telemedicine, rising consumer interest in wellness and self-care, increasing focus on preventive healthcare, and adoption of biosimilars and generic drugs. Major trends in the forecast period include innovation in drug delivery technologies, advancements in drug formulation, integration of wearable devices in treatment monitoring, integration of AI and machine learning in treatment decision making, and technological innovations in drug manufacturing.
The rising prevalence of migraines is expected to drive the growth of the vyepti market in the coming years. Migraines are intense headaches often accompanied by symptoms such as nausea, vomiting, and sensitivity to light or sound. Several factors contribute to the prevalence of migraines, including genetic, environmental, and lifestyle influences such as hormonal changes, stress, sleep disturbances, and certain dietary triggers. Vyepti (eptinezumab) treats migraines by targeting and inhibiting the CGRP (calcitonin gene-related peptide) protein, which plays a crucial role in the development of migraine headaches, thereby reducing both the frequency and severity of migraines. According to the Association of Migraine Disorders, in October 2023, migraines affect around 1 in 7 individuals globally, with women experiencing them more frequently, with 17-19% affected compared to 5-7% in men. In the United States, over 35 million people suffer from migraines, with most of them being between the ages of 35 and 45. This increasing prevalence is fueling the growth of the vyepti market.
Increasing healthcare investment and access are also expected to contribute to the growth of the vyepti market in the future. Healthcare investment and access refer to efforts to enhance healthcare systems, ensuring that individuals have access to affordable, high-quality care. This growth is driven by factors such as aging populations, global health challenges, efforts to reduce healthcare disparities, rising costs, and greater public awareness. As healthcare investment and access increase, it improves service quality, fosters innovation, and creates more opportunities for growth in sectors such as Vyepti through expanded funding for research and broader access to advancements. For example, according to the Office of National Statistics in May 2024, total healthcare expenditure in the UK grew by 5.6% in nominal terms between 2022 and 2023, compared to a 0.9% growth in 2022. Therefore, increased healthcare investment and access are playing a key role in driving the growth of the vyepti market.
A key trend in the vyepti market is the development of innovative intravenous (IV) treatments for migraine relief, aiming to improve both efficacy and patient convenience. IV treatment involves delivering medication directly into a vein for rapid relief from severe migraine symptoms, especially when oral medications are not effective. In January 2022, H. Lundbeck A/S, a Denmark-based pharmaceutical company, received approval from the European Commission for Vyepti (eptinezumab) in the European Union (EU) as a preventive treatment for migraines in adults. Vyepti is a humanized monoclonal antibody that targets CGRP, a molecule involved in migraine attacks, and is designed for intravenous administration, providing both quick and sustained relief from migraine symptoms.
The key company operating in the vyepti market is H. Lundbeck A/S.
North America was the largest region in the vyepti market in 2024. The regions covered in vyepti report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vyepti market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Vyepti (eptinezumab-jjmr) is a medication used to prevent chronic migraines in adults. It is a monoclonal antibody that targets and inhibits calcitonin gene-related peptide (CGRP), a protein involved in transmitting pain associated with migraines. Vyepti provides a treatment option for individuals experiencing chronic migraines, helping to reduce the frequency of migraine attacks and improve their quality of life.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for vyepti include chronic migraine, episodic migraine, and other neurological conditions. Chronic migraine is a neurological disorder characterized by headaches occurring 15 or more days per month for at least three months, significantly impacting daily life. Vyepti is distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and is used by a range of end users, including adults and geriatric patients.
The vyepti market consists of sales of vyepti injection, IV infusion supplies, sterile accessories, and storage equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The growth in the forecast period can be attributed to shift towards personalized medicine, growth of telemedicine, rising consumer interest in wellness and self-care, increasing focus on preventive healthcare, and adoption of biosimilars and generic drugs. Major trends in the forecast period include innovation in drug delivery technologies, advancements in drug formulation, integration of wearable devices in treatment monitoring, integration of AI and machine learning in treatment decision making, and technological innovations in drug manufacturing.
The rising prevalence of migraines is expected to drive the growth of the vyepti market in the coming years. Migraines are intense headaches often accompanied by symptoms such as nausea, vomiting, and sensitivity to light or sound. Several factors contribute to the prevalence of migraines, including genetic, environmental, and lifestyle influences such as hormonal changes, stress, sleep disturbances, and certain dietary triggers. Vyepti (eptinezumab) treats migraines by targeting and inhibiting the CGRP (calcitonin gene-related peptide) protein, which plays a crucial role in the development of migraine headaches, thereby reducing both the frequency and severity of migraines. According to the Association of Migraine Disorders, in October 2023, migraines affect around 1 in 7 individuals globally, with women experiencing them more frequently, with 17-19% affected compared to 5-7% in men. In the United States, over 35 million people suffer from migraines, with most of them being between the ages of 35 and 45. This increasing prevalence is fueling the growth of the vyepti market.
Increasing healthcare investment and access are also expected to contribute to the growth of the vyepti market in the future. Healthcare investment and access refer to efforts to enhance healthcare systems, ensuring that individuals have access to affordable, high-quality care. This growth is driven by factors such as aging populations, global health challenges, efforts to reduce healthcare disparities, rising costs, and greater public awareness. As healthcare investment and access increase, it improves service quality, fosters innovation, and creates more opportunities for growth in sectors such as Vyepti through expanded funding for research and broader access to advancements. For example, according to the Office of National Statistics in May 2024, total healthcare expenditure in the UK grew by 5.6% in nominal terms between 2022 and 2023, compared to a 0.9% growth in 2022. Therefore, increased healthcare investment and access are playing a key role in driving the growth of the vyepti market.
A key trend in the vyepti market is the development of innovative intravenous (IV) treatments for migraine relief, aiming to improve both efficacy and patient convenience. IV treatment involves delivering medication directly into a vein for rapid relief from severe migraine symptoms, especially when oral medications are not effective. In January 2022, H. Lundbeck A/S, a Denmark-based pharmaceutical company, received approval from the European Commission for Vyepti (eptinezumab) in the European Union (EU) as a preventive treatment for migraines in adults. Vyepti is a humanized monoclonal antibody that targets CGRP, a molecule involved in migraine attacks, and is designed for intravenous administration, providing both quick and sustained relief from migraine symptoms.
The key company operating in the vyepti market is H. Lundbeck A/S.
North America was the largest region in the vyepti market in 2024. The regions covered in vyepti report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the vyepti market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Vyepti (eptinezumab-jjmr) is a medication used to prevent chronic migraines in adults. It is a monoclonal antibody that targets and inhibits calcitonin gene-related peptide (CGRP), a protein involved in transmitting pain associated with migraines. Vyepti provides a treatment option for individuals experiencing chronic migraines, helping to reduce the frequency of migraine attacks and improve their quality of life.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The main indications for vyepti include chronic migraine, episodic migraine, and other neurological conditions. Chronic migraine is a neurological disorder characterized by headaches occurring 15 or more days per month for at least three months, significantly impacting daily life. Vyepti is distributed through various channels, such as hospital pharmacies, retail pharmacies, and online pharmacies, and is used by a range of end users, including adults and geriatric patients.
The vyepti market consists of sales of vyepti injection, IV infusion supplies, sterile accessories, and storage equipment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Vyepti Market Characteristics4. Vyepti Market Trends And Strategies5. Vyepti Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market7. Global Vyepti Pricing Analysis & Forecasts30. Global Vyepti Market Competitive Benchmarking And Dashboard31. Key Mergers And Acquisitions In The Vyepti Market32. Recent Developments In The Vyepti Market
3. Vyepti Market Biologic Drug Characteristics
6. Global Vyepti Growth Analysis And Strategic Analysis Framework
8. Vyepti Market Segmentation
9. Global Vyepti Epidemiology Of Clinical Indications
10. Vyepti Market Regional And Country Analysis
11. Asia-Pacific Vyepti Market
12. China Vyepti Market
13. India Vyepti Market
14. Japan Vyepti Market
15. Australia Vyepti Market
16. South Korea Vyepti Market
17. Western Europe Vyepti Market
18. UK Vyepti Market
19. Germany Vyepti Market
20. France Vyepti Market
21. Eastern Europe Vyepti Market
22. North America Vyepti Market
23. USA Vyepti Market
24. Canada Vyepti Market
25. South America Vyepti Market
26. Middle East Vyepti Market
27. Africa Vyepti Market
28. Vyepti Market Competitive Landscape And Company Profiles
29. Global Vyepti Market Pipeline Analysis
33. Vyepti Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Vyepti Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on vyepti market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for vyepti ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The vyepti market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Indication: Chronic Migraine; Episodic Migraine; Other Neurological Indications2) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
3) By End User: Adult; Geriatric
Key Companies Profiled: H. Lundbeck A/S.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- H. Lundbeck A/S.
